Literature DB >> 16433777

Preemptive retransplantation for BK virus nephropathy: successful outcome despite active viremia.

K L Womer1, H-U Meier-Kriesche, P R Patton, K Dibadj, C M Bucci, D Foley, S Fujita, B P Croker, R J Howard, T R Srinivas, B Kaplan.   

Abstract

BK virus nephropathy (BKVN) is now recognized as a major cause of renal allograft loss. Recent reports suggest that retransplantation in patients with graft loss due to BKVN is safe after return to dialysis. Since early transplantation is associated with improved outcomes, it would be advantageous if this procedure could be performed prior to ultimate graft loss. However, little data are available regarding the safety of this approach during active viremia. In this report, we describe successful preemptive retransplantation with simultaneous allograft nephrectomy in two patients with active BKVN and viremia at the time of surgery. With 21- and 12-month follow-up, respectively, both patients have stable allograft function and no evidence for active viral replication. We conclude that preemptive retransplantation can be considered in patients with failing allografts due to BKVN.

Entities:  

Mesh:

Year:  2006        PMID: 16433777     DOI: 10.1111/j.1600-6143.2005.01137.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  4 in total

Review 1.  Polyomavirus-associated nephropathy.

Authors:  Cristina Costa; Rossana Cavallo
Journal:  World J Transplant       Date:  2012-12-24

2.  Kidney retransplantation for BK virus nephropathy with active viremia without allograft nephrectomy.

Authors:  Jingbo Huang; Gabriel Danovitch; Phuong-Thu Pham; Suphamai Bunnapradist; Edmund Huang
Journal:  J Nephrol       Date:  2015-04-25       Impact factor: 3.902

Review 3.  Recent developments in kidney transplantation--a critical assessment.

Authors:  K L Womer; B Kaplan
Journal:  Am J Transplant       Date:  2009-05-13       Impact factor: 8.086

Review 4.  BK virus nephritis after renal transplantation.

Authors:  Aaron Dall; Sundaram Hariharan
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.